Several PARP-1 inhibitors are currently in phase I or II of clinical monotherapy trials in BRCA1/BRCA2-deficient breast or ovarian cancers (Helleday et al, 2008; Lord and Ashworth, 2008). This evidence concerns the gene BRCA2 and ovarian cancer.